Previous close | 2,015.00 |
Open | 0.00 |
Bid | 1,850.15 x N/A |
Ask | 0.00 x N/A |
Day's range | 2,015.00 - 2,015.00 |
52-week range | 1,850.11 - 2,483.11 |
Volume | |
Avg. volume | 1 |
Market cap | 414.542B |
Beta (5Y monthly) | 1.02 |
PE ratio (TTM) | 23.70 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 17.42 (0.86%) |
Ex-dividend date | 26 Jun 2024 |
1y target est | N/A |
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Devdatt "Dev" Kurdikar, President, Chief Executive Officer and a member of the board of directors of Embecta Corp. (embecta), has been appointed to the Zimmer Biomet Board, effective immediately. embecta (Nasdaq: EMBC), formerly part of Becton, Dickinson and Company (BD), is one of the largest pure-play diabetes management companies in the world.
RevelAi Health and Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced a multi-year co-marketing agreement to commercialize generative artificial intelligence (AI)-powered engagement solutions that advance value-based orthopedic care and health equity. During the multi-year agreement, Zimmer Biomet will commercialize RevelAi Health's patient care-management platform, care team dashboard for providers, and any future products or services.
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced a limited distribution agreement with THINK Surgical, Inc. regarding its wireless, handheld, TMINI Miniature Robotic System for total knee arthroplasty. The agreement will result in an exclusive offering, integrating Zimmer Biomet technology into a customized TMINI robotic solution. The TMINI system complements Zimmer Biomet's comprehensive, flagship ROSA® Robotics portfolio with a handheld robo